Sanofi-Aventis’ Acomplia shows benefits in Type 2 diabetes study
New data shows that Sanofi-Aventis’ developmental drug Acomplia (rimonabant) significantly improved blood sugar levels in trial patients with Type 2 ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Your message:
The e-mail address(es) that you supply to use this service will only be used to send the requested article.